The FDA has approved Lumakras with Vectibix for adults with KRAS G12C-mutated metastatic colorectal cancer who received ...

The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Biopharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication ...

The FDA granted an encorafenib-led combination accelerated approval for the treatment of certain patients with metastatic colorectal cancer. The indication applies to use of the agent for patients ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...

Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer. Invikafusp alfa ...

FDA approved Braftovi, Erbitux, and mFOLFOX6 for BRAF V600E mutation-positive metastatic colorectal cancer. BREAKWATER trial showed a 61% objective response rate for the treatment group versus 40% for ...